VHAM
IBB icon

Van Hulzen Asset Management’s iShares Biotechnology ETF IBB Stock Holding History

Van Hulzen Asset Management’s Portfolio IBB Stock Details IBB Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2025
Q1 		– Sell
-285
Closed -$37.7K – 641
2024
Q4 		$37.7K Buy
+285
New +$40.1K ﹤0.01% 564
2018
Q1 		– Sell
-2,565
Closed -$274K – 219
2017
Q4 		$274K Buy
+2,565
New +$274K 0.08% 166

Other funds holding IBB

Bank of America
Bank of America Charlotte, North Carolina $1.37T AUM 24.88% 1-Year Est. Return
Citigroup
Citigroup New York $235B AUM 32.99% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return
UBS Group
UBS Group Zurich, Switzerland $666B AUM 30.12% 1-Year Est. Return
BNP Paribas Financial Markets
BNP Paribas Financial Markets Paris, France $206B AUM 31.61% 1-Year Est. Return
Wells Fargo
Wells Fargo San Francisco, California $530B AUM 22.01% 1-Year Est. Return
Healthcare of Ontario Pension Plan (HOOPP) Trust Fund
Healthcare of Ontario Pension Plan (HOOPP) Trust Fund Toronto, Ontario, Canada $62.2B AUM 31.35% 1-Year Est. Return
Royal Bank of Canada
Royal Bank of Canada Toronto, Ontario, Canada $570B AUM 27.57% 1-Year Est. Return
Barclays
Barclays London, United Kingdom $416B AUM 33.63% 1-Year Est. Return
MMEA
Main Management ETF Advisors San Francisco, California $2.68B AUM 24.27% 1-Year Est. Return

Van Hulzen Asset Management's IBB Position: Q1 2025 in Review

Van Hulzen Asset Management sold out of iShares Biotechnology ETF (IBB) in Q1 2025, closing a stake of 285 shares — an estimated $37.7K sold.

Van Hulzen Asset Management first reported a position in IBB in Q4 2017 and held it in 2 quarters. The position peaked at $274K in Q4 2017. 831 funds tracked by Wall St. Rank hold IBB as of Q1 2025.

  • Van Hulzen Asset Management reported no remaining iShares Biotechnology ETF position as of Q1 2025 after selling out during the quarter.
  • Van Hulzen Asset Management sold 285 iShares Biotechnology ETF shares in Q1 2025, an estimated $37.7K.
  • Van Hulzen Asset Management first reported a position in iShares Biotechnology ETF in Q4 2017 and held it in 2 quarters.
  • Van Hulzen Asset Management's iShares Biotechnology ETF position peaked at $274K in Q4 2017.
  • 831 funds tracked by Wall St. Rank held iShares Biotechnology ETF as of Q1 2025.

Based on Van Hulzen Asset Management's 13F filing for Q1 2025, filed 14 May 2025.